Researchers at Wageningen University & Research (WUR) in the Netherlands have made a significant breakthrough in cannabis research by resurrecting ancient enzymes responsible for producing key cannabinoids. This groundbreaking study not only sheds light on the evolutionary history of cannabis but also opens up new avenues for drug development and biotechnology.
Cannabis produces a variety of bioactive compounds, including tetrahydrocannabinol (THC) and cannabidiol (CBD), but the evolutionary mechanisms behind their synthesis have remained largely unknown. By employing a technique called ancestral sequence reconstruction, researchers reconstructed ancient proteins from modern genetic data. This allowed them to identify how early cannabis ancestors synthesized cannabinoids, revealing that these ancient enzymes were versatile generalists capable of producing multiple compounds, including THC, CBD, and cannabichromene (CBC).
The research team, led by Robin van Velzen and his colleague Cloé Villard, discovered that the ancient enzymes differed significantly from modern counterparts, which tend to be highly specialized. “What once seemed evolutionarily ‘unfinished’ turns out to be highly useful,” van Velzen stated. The ancestral enzymes demonstrated greater robustness and flexibility, characteristics that could have valuable applications in biotechnology and pharmaceutical research.
Uncovering the Potential of Cannabichromene
While much of the focus in cannabis research has been on THC and CBD, the study highlights the potential of CBC, a lesser-known cannabinoid. Modern cannabis plants typically contain less than 1% CBC, making it challenging to study and produce in significant quantities. Van Velzen noted, “At present, there is no cannabis plant with a naturally high CBC content. Introducing this enzyme into a cannabis plant could therefore lead to innovative medicinal varieties.”
Preliminary studies suggest that CBC may possess anti-inflammatory, anticonvulsant, and antibacterial properties, but its therapeutic potential has not been extensively explored compared to THC and CBD. The findings from this study could pave the way for new cannabis strains with higher CBC content, offering exciting opportunities for medical applications.
The research also indicated that the reconstructed ancestral enzymes could be produced more easily in microorganisms, such as yeast cells, compared to modern enzymes. This efficiency means that cannabinoids could potentially be synthesized without the need for extensive plant cultivation, a development that could have major implications for both research and drug development.
Implications for Biotechnology and Drug Development
The team’s approach involved rational engineering of the ancestral enzymes, allowing them to identify key amino acid mutations that have influenced the evolution of cannabinoid oxidocyclases. The study contributes to a deeper understanding of cannabinoid synthesis and opens new perspectives for breeding, biotechnological applications, and medicinal use.
“Ancestral and hybrid enzymes also displayed unique activities and proved to be easier to produce heterologously than their extant counterparts,” the researchers noted. This aspect of the study highlights the potential for developing efficient methods for cannabinoid production, which could significantly enhance the availability of these compounds for various applications.
Published in the Plant Biotechnology Journal, this research represents a significant step forward in cannabis science. It provides a clearer picture of the evolutionary processes that shaped cannabis and lays the groundwork for future innovations in medicine and biotechnology. The potential for new cannabis varieties and enhanced drug development could have a lasting impact on the field, driving further exploration of the plant’s therapeutic capabilities.
